Close Menu

NEW YORK (GenomeWeb) – Exact Sciences reported after the close of the market on Tuesday that its first quarter revenues rose 79 percent year over year, thanks to a corresponding 79 percent increase in testing volumes for its Cologuard colorectal cancer screening test.

For the three months ended March 31, the Madison, Wisconsin-based molecular diagnostics company reported revenues of $162.0 million, compared to $90.3 million a year earlier, and beating the average Wall Street analyst estimate of $153.0 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Forensic genetic firm Verogen has bought the genetic genealogy site GEDmatch.

Researchers have 3D-printed plastic bunnies that encase the information needed to make more such bunnies in DNA, according to Discover magazine.

Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.

In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.